论文部分内容阅读
司莫司汀(Semusfine,又名甲环亚硝脲MECCNU)和采托蒽醌(Mitoxautrone,Novautrone)是上海医药工业研究院近年研制的抗肿瘤药物,前者已由浙南制药厂投产上市,后者于1985年批准临床,目前即将完成300例以上的临床研究。现分别有所侧重地简介如下:
Semusfine (aka MENUNU) and Mitoxautrone (Novautrone) are anti-tumor drugs developed by the Shanghai Institute of Pharmaceutical Industry in recent years. The former has been put on the market from the Zhejiang South Pharmaceutical Factory. The patient was approved clinically in 1985 and is currently completing more than 300 clinical studies. Here are some of the highlights of the introduction: